Literature DB >> 12697735

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.

Claudia Curcio1, Emma Di Carlo, Raphael Clynes, Mark J Smyth, Katia Boggio, Elena Quaglino, Michela Spadaro, Mario P Colombo, Augusto Amici, Pier-Luigi Lollini, Piero Musiani, Guido Forni.   

Abstract

Since the mechanisms by which specific immunity destroys Her-2/neu carcinoma cells are highly undetermined, these were assessed in BALB/c mice vaccinated with plasmids encoding extracellular and transmembrane domains of the protein product (p185(neu)) of the rat Her-2/neu oncogene shot into the skin by gene gun. Vaccinated mice rejected a lethal challenge of TUBO carcinoma cells expressing p185(neu). Depletion of CD4 T cells during immunization abolished the protection, while depletion of CD8 cells during the effector phase halved it, and depletion of polymorphonuclear granulocytes abolished all protection. By contrast, Ig mu-chain gene KO mice, as well as Fcgamma receptor I/III, beta-2 microglobulin, CD1, monocyte chemoattractant protein 1 (MCP1), IFN-gamma, and perforin gene KO mice were protected. Only mice with both IFN-gamma and perforin gene KOs were not protected. Although immunization also cured all BALB/c mice bearing established TUBO carcinomas, it did not cure any of the perforin KO or perforin and IFN-gamma KO mice. Few mice were cured that had knockouts of the gene for Ig mu-chain, Fcgamma receptor I/III, IFN-gamma, or beta-2 microglobulin. Moreover, vaccination cured half of the CD1 and the majority of the MCP1 KO mice. The eradication of established p185(neu) carcinomas involves distinct mechanisms, each endowed with a different curative potential.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12697735      PMCID: PMC152940          DOI: 10.1172/JCI17426

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  59 in total

1.  Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.

Authors:  P L Ward; H K Koeppen; T Hurteau; D A Rowley; H Schreiber
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

2.  CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells.

Authors:  P A Monach; H Schreiber; D A Rowley
Journal:  Transplantation       Date:  1993-06       Impact factor: 4.939

3.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

Authors:  M L Disis; E Calenoff; G McLaughlin; A E Murphy; W Chen; B Groner; M Jeschke; N Lydon; E McGlynn; R B Livingston
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

4.  Prevention of breast tumour development in vivo by downregulation of the p185neu receptor.

Authors:  M Katsumata; T Okudaira; A Samanta; D P Clark; J A Drebin; P Jolicoeur; M I Greene
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

Review 5.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

6.  An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.

Authors:  F Pericle; M Giovarelli; M P Colombo; G Ferrari; P Musiani; A Modesti; F Cavallo; F Di Pierro; F Novelli; G Forni
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

7.  Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.

Authors:  J A Drebin; V C Link; M I Greene
Journal:  Oncogene       Date:  1988-04       Impact factor: 9.867

8.  Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.

Authors:  Kavita M Dhodapkar; Joseph Krasovsky; Barbara Williamson; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

9.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.

Authors:  W J Gullick; S B Love; C Wright; D M Barnes; B Gusterson; A L Harris; D G Altman
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

10.  Antibodies against p53 are associated with poor prognosis of colorectal cancer.

Authors:  J G Houbiers; S H van der Burg; L M van de Watering; R A Tollenaar; A Brand; C J van de Velde; C J Melief
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more
  26 in total

1.  Coordinated tumor immunity.

Authors:  Glenn Dranoff
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 2.  Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.

Authors:  E M Tan; F-D Shi
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

3.  Oncoantigens for an immune prevention of cancer.

Authors:  Elisabetta Bolli; Elena Quaglino; Maddalena Arigoni; Pier-Luigi Lollini; Raffaele Calogero; Guido Forni; Federica Cavallo
Journal:  Am J Cancer Res       Date:  2010-12-20       Impact factor: 6.166

4.  Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.

Authors:  Andrew Gray; Maria de la Luz Garcia-Hernandez; Myrna van West; Shreya Kanodia; Bolyn Hubby; W Martin Kast
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

5.  CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.

Authors:  T Nguyen-Hoai; M Pham-Duc; M Gries; B Dörken; A Pezzutto; J Westermann
Journal:  Cancer Gene Ther       Date:  2016-04-08       Impact factor: 5.987

6.  A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors.

Authors:  Maddalena Arigoni; Giuseppina Barutello; Stefania Lanzardo; Dario Longo; Silvio Aime; Claudia Curcio; Manuela Iezzi; Yujuan Zheng; Irmeli Barkefors; Lars Holmgren; Federica Cavallo
Journal:  Angiogenesis       Date:  2012-03-17       Impact factor: 9.596

7.  Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model.

Authors:  Nafiseh Pakravan; Ladan Langroudi; Monire Hajimoradi; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2010-06-12       Impact factor: 3.667

8.  Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.

Authors:  Nafiseh Pakravan; Seyed Mahmoud Hashemi; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2010-08-22       Impact factor: 3.667

Review 9.  Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Authors:  Leisha A Emens
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

10.  Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.

Authors:  Mary L Disis; Vivian Goodell; Kathy Schiffman; Keith L Knutson
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.